Nama's AI scorecard currently rates Perrigo Hold (5.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PRGO's P/E ratio?

Perrigo trades at a trailing price-to-earnings ratio of 6.9.

When does PRGO report earnings?

Perrigo's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.72.

What is the PRGO price target?

The median analyst price target from 3 analysts is $19.00, with a range of $15.00 – $20.00.

Is PRGO Shariah compliant?

Nama's AAOIFI-style screen reads Perrigo as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does PRGO pay a dividend?

Yes — Perrigo's dividend yield is 7.3%.

Nama Insights

Perrigo (PRGO)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Perrigo (PRGO) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $2.20B, a trailing price-to-earnings ratio of 6.9 and a free-cash-flow yield of 6.6%. Over the most recent reported fiscal year, revenue declined 2.8% and free cash flow per share fell 41.1%. Nama's AI scorecard rates it Hold, 5.3 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.3/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -2.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-66.9%

How far the last close sits under the highest price of the past five years.

Market cap	$2.20B
Trailing P/E	6.9
Price / book	0.9
Price / sales	0.5
FCF yield	6.6%
Dividend yield	7.3%
Gross margin	33.3%
Operating margin	6.0%
Net margin	-41.9%
Revenue growth (YoY)	-2.8%
Revenue growth (3-yr annual)	-1.5%
EPS growth (YoY)	+7.0%
FCF/share growth (YoY)	-41.1%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

PRGO earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.72). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.60	$0.53	+13.2%	$988.60M
Q2 2026	Aug 5, 2026	$0.50	$0.36	+38.9%	$1.02B
Q1 2026	May 6, 2026	$0.43	$0.31	+38.7%	$969.20M
Q4 2025	Feb 26, 2026	$0.77	$0.78	-1.3%	$1.11B

PRGO analyst price target

Median target $19.00 from 3 analysts, ranging $15.00 – $20.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live PRGO data on Nama Insights →

Recent Congressional trades

Perrigo trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Susan M Collins	Senate	Buy	$15,001 - $50,000	—
James M Inhofe	Senate	Sell	$50,001 - $100,000	—
James M Inhofe	Senate	Buy	$50,001 - $100,000	—
Susan M Collins	Senate	Buy	$1,001 - $15,000	—

PRGO FAQ

Is PRGO a buy?: Nama's AI scorecard currently rates Perrigo Hold (5.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PRGO's P/E ratio?: Perrigo trades at a trailing price-to-earnings ratio of 6.9.
When does PRGO report earnings?: Perrigo's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.72.
What is the PRGO price target?: The median analyst price target from 3 analysts is $19.00, with a range of $15.00 – $20.00.
Is PRGO Shariah compliant?: Nama's AAOIFI-style screen reads Perrigo as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does PRGO pay a dividend?: Yes — Perrigo's dividend yield is 7.3%.